
Name
PELF
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for PELF
Name
Alternate Names
4'-Epiadriamycin Hydrochloride
4'-Epidoxorubicin
4-EA
Ellence
Epidoxorubicin
Epidoxorubicin Hydrochloride
Epirubicin Hydrochloride
IMI-28
Pharmorubicin
Pidorubicin Hydrochloride
Abbreviations
EPI
epi-ADR
Category
Chemotherapy
Subcategory
Anthracycline
Antitumor antibiotic
NSC Number
256942
Primary Site
Histology
None
Remarks
Coding
This drug should be coded
Name
Alternate Names
5-Fluorouracil
5-Fluracil
Adrucil
Efudex
Fluoroplex
Fluracil
Fluril
Oracil
Ro 2-9757
WR-69596
Abbreviations
5-FU
5FU
FU
Category
Chemotherapy
Subcategory
Antimetabolite
NSC Number
019893
19893
Primary Site
Breast- adjuvant setting and advanced disease
colorectal- adjuvant setting and advanced disease
GI malignancies: anal, esophageal, gastric and pancreatic
Hepatoma
Ovarian cancer
Histology
None
Remarks
Fluorinated pyrimidine; antimetabolite. FDA approved uses on basal cell carcinoma, breast cancer, colorectal cancer, gastric cancer, and pancreatic cancer.
Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.
Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.
Coding
This drug should be coded
Name
Alternate Names
Cis-Platin
Cis-Platinum II#
Cisplatino (Spanish)
Cisplatinum
Cisplatyl
Neoplatin
Peyrone's chloride
Platinex
Platinol
Platinol-AQ
Platinol-AQ VHA Plus
Platinum
Abbreviations
CACP
CDDP
Cis-DDP
CPD
CPDC
CPDD
CPPD
DDP
Category
Chemotherapy
Subcategory
Alkylating agent
Platinum analog
NSC Number
119875
Primary Site
Histology
None
Remarks
An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.
Coding
This drug should be coded
Name
Alternate Names
Calcium folinate
Calcium leucovorin
Calcium leucovorin rescue
Citrovorum Factor
Citrovorum factor rescue
Folic acid
Folinic Acid
Lederfoline
Leucosar
Leucovorin Calcium
Leucovorin rescue
Wellcovorin
Abbreviations
C.F.
CF
CL
Category
Ancillary Agent
Subcategory
None
NSC Number
3590
003590
Primary Site
None
Histology
None
Remarks
The pharmacologically active form of folic acid. FDA approved uses as 1st line colorectal carcinoma in combination with 5-FU and to diminish methotrexate toxicity.
Coding
This drug should NOT be coded
Name
Alternate Names
G-CSF
GCSF
Neupogen
Recombinant human granulocyte colony-stimulating factor
Zarxio
r-G-CSF
r-met Hu G-CSF
rhG-CSF
Abbreviations
None
Category
Ancillary Agent
Subcategory
None
NSC Number
614371
614629
Primary Site
None
Histology
None
Remarks
A granulocyte colony-stimulating factor (G-CSF). Adjunct of Ganciclovir therapy; treatment of neutropenia
March 2015: Zarxio is the first biosimilar product approved in the United States. A biosimilar product is a biological product that is based on a showing that it is highly similar to an already-approved biological product, known as a reference product. There are no differences in terms of safety and effectiveness from the reference product (neupogen)
March 2015: Zarxio is the first biosimilar product approved in the United States. A biosimilar product is a biological product that is based on a showing that it is highly similar to an already-approved biological product, known as a reference product. There are no differences in terms of safety and effectiveness from the reference product (neupogen)
Coding
This drug should NOT be coded
